Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Synthetic MR AB's Debt-to-EBITDA or its related term are showing as below:
LTS:0G79'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.13 Med: 0.11 Max: 0.17
Current: -0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Synthetic MR AB was 0.17. The lowest was -0.13. And the median was 0.11.
LTS:0G79's Debt-to-EBITDA is ranked worse than 100% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs LTS:0G79: -0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Synthetic MR AB Debt-to-EBITDA Related Terms
Synthetic MR AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0G79 vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Synthetic MR AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Synthetic MR AB (LTS:0G79) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synthetic MR AB. According to the industry distribution chart, Synthetic MR AB ranks #999999 out of 477 companies in the Healthcare Providers & Services industry.
Is Synthetic MR AB's Debt-to-EBITDA too high?
Synthetic MR AB's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Synthetic MR AB ranks #999999 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #999999 out of 477 companies for Debt-to-EBITDA. This places Synthetic MR AB in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synthetic MR AB. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synthetic MR AB's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Synthetic MR AB (LTS:0G79) has a current Debt-to-EBITDA of 0.00. The stock's GF Value™ is kr114.94, compared to a current price of kr16.23 — trading 85.9% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Synthetic MR AB (LTS:0G79), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (LTS:0G79) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of kr16.23 is trading 85.9% below its estimated GF Value™ of kr114.94.
Key valuation signals for LTS:0G79:
Debt-to-EBITDA: 0.00
GF Value™: kr114.94 vs. price of kr16.23 (85.9% below fair value)
No single metric tells the full story. See the LTS:0G79 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for LTS:0G79
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G79 has been successfully added to your 
